annual meeting program - American Society of Clinical Oncology

Saturday, June 5, 2010
Brd. 51B Sequential angiogenic blockade for the treatment of recurrent ovarian
cancer. (Abstract #5083)
U. Matulonis, L. Pereira, H. Lee, S. M. Campos, J. Liu, J. Lee, C. Whalen,
T. Atkinson, M. Hill, S. T. Berlin
Brd. 51C Interval from neoadjuvant chemotherapy to interval debulking surgery in
advanced ovarian cancer: Is this a prognostic indicator? (Abstract #5084)
R. Hariprasad, L. Kumar, A. Mookerjee, V. Radhakrishnan, S. Kumar, S. Mathur,
S. Thulkar
Brd. 51D Associations between age and quality of life in advanced ovarian cancer.
(Abstract #5085)
A. A. Wright, L. Pereira, M. E. Nilsson, C. Gibson, S. M. Campos, M. Roche,
S. T. Berlin, C. N. Krasner, R. T. Penson, U. Matulonis
Brd. 51E Effects of treatment by temsirolimus on patients with clear cell carcinoma of
the ovary. (Abstract #5086)
Y. Kikuchi, K. Kudoh, M. Takano, R. Kikuchi, T. Kita, Y. Hamada, S. Nagao,
K. Fujiwara, T. Shiozawa, D. Aoki
Brd. 51F Regulation of proliferation in endometrial carcinoma cell line by the
epidermal growth factor receptor and estrogen receptor beta. (Abstract
#5087)
J. H. Farley, M. Clark, T. J. Wu
Brd. 51G Circulating biomarker tissue kallikrein-related peptidase KLK5 impacts
ovarian cancer patients’ survival. (Abstract #5088)
J. Dorn, T. Schuster, A. Gkazepis, M. Kiechle, E. P. Diamandis, A. Harlozinska,
V. Magdolen, M. Schmitt
Brd. 51H Interleukin-6 as a therapeutic target in advanced ovarian cancer. (Abstract
#5089)
J. I. Coward, H. Kulbe, D. Leader, M. Quigley, R. Thompson, A. Leinster,
J. Nemeth, J. Vermeulen, I. McNeish, F. Balkwill
Brd. 52A Relative conditional survival in 41,476 patients with ovarian cancer. (Abstract
#5090)
R. Ware, L. Baldwin, B. Huang, T. Tucker, S. Goodrich, I. Podzielinski,
C. P. DeSimone, F. Ueland, J. Vannagell, L. G. Seamon
Brd. 52B Fertility-sparing management with progestin for young women with earlystage
endometrial cancer and complex hyperplasia with atypia. (Abstract
#5091)
J. Park, H. Roh, W. Joo, H. You, D. Kim, J. Kim, Y. Kim, J. Nam
Brd. 52C Oxaliplatin plus continuous infusion topotecan: An ongoing phase II study
for recurrent ovarian cancer—A New York Cancer Consortium study
(#N01-CM62204). (Abstract #5092)
S. Stein, H. S. Hochster, F. Muggia, S. V. Blank, J. P. Curtin, I. Shapira,
G. L. Goldberg, A. Tiersten
Brd. 52D Combination therapy with paclitaxel, carboplatin, and megesterol acetate for
advanced-stage and recurrent endometrial carcinoma: A phase II study.
(Abstract #5093)
K. S. Bevis, L. C. Kilgore, R. D. Alvarez, J. M. Straughn, C. A. Leath
Brd. 52E Rapid, durable restoration of malignant ascites-derived antigen presenting
cell immunogenicity by toll-like receptor agonists. (Abstract #5094)
S. Jean, S. F. Adams, A. Facciabene, X. Peng, G. Coukos
Brd. 52F Vaginal cuff brachytherapy combined with carboplatin and paclitaxel as
adjuvant therapy for high-intermediate-risk patients with endometrial
carcinoma. (Abstract #5095)
L. M. Landrum, R. S. Mannel, K. N. Moore, J. L. Walker, E. J. Syzek, R. E. Zuna,
D. S. McMeekin
173
SATURDAY